Cantor Fitzgerald reissued their overweight rating on shares of Atossa Therapeutics (NASDAQ:ATOS – Free Report) in a research note published on Tuesday morning, Benzinga reports. A number of other brokerages have also weighed in on ATOS. HC Wainwright lifted their price target on shares of Atossa Therapeutics from $4.00 to $6.00 and gave the company […]